Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure

Nephrology

Volumn 11, Issue 2, 2006, Pages 137-141

  Bernasconi, Amelia R ^a   Liste, Andrés ^a   Del Pino, Noemí ^b   Rosa Diez, Guillermo J ^c   Heguilén, Ricardo M ^a,d  

^a HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^b Laboratorio APUNLAB   (Argentina)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Chronic renal failure; Folic acid; Hyperhomocysteinaemia; Pre dialysis

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; THIAMINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEQUENTIAL ANALYSIS; THORAX RADIOGRAPHY; VITAMIN SUPPLEMENTATION;

AGED; DOUBLE-BLIND METHOD; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL REPLACEMENT THERAPY; VITAMIN B COMPLEX;

EID: 33645895574     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00536.x     Document Type: Article

References (50)

1. Clarke R Daly L Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 1991 324 1149 55.
2. Austen SK Coombes JS Fassett RG. Homocysteine and cardiovascular disease in renal disease. Nephrology 2003 8 285 95.
3. Buccianti G Baragetti I Bamonti F Furiani S Dorighet V Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J. Nephrol. 2004 17 405 10.
4. Ducloux D Motte G Challier B Gibey R Chalopin JM. Serum Total Homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J. Am. Soc. Nephrol. 2000 11 134 7.
5. Perna AF Castaldo P Ingrosso D De Santo NG. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J. Nephrol. 1999 12 230 40.
6. Selhub J Jacques PF Bostom AG et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 1995 322 286 91.
7. Scott JM. Homocysteine and cardiovascular risk. Am. J. Clin. Nutr. 2000 72 333 4.
8. Perna AF Ingrosso D Lombardi C et al. Possible mechanisms of homocysteine toxicity. Kidney Int. 2003 63 Suppl. 84 S137 S140.
9. Clarke R Stanbie D. Assessment of homocysteine as a cardiovascular risk factor in clinical practice. Ann. Clin. Biochem. 2001 38 624 32.
10. Nyagard O Nordrehaug JE Refsum H Ueland PM Farstad M Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 1997 337 230 36.
11. Van Guldener C Stehouwer CD. Homocysteine metabolism in renal disease. Clin. Chem. Lab. Med. 2003 41 1412 17.
12. Friedman AN Bostom AG Selhub AJ Levey AS Rosenberg IH. The kidney and homocysteine metabolism. J. Am. Soc. Nephrol. 2001 12 2181 9.
13. Guttormsen AB Ueland PM Svarstad E Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int. 1997 52 495 502.
14. Van Guldener C Kulik W Berger R et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int. 1999 56 1064 71.
15. Wollesen F Brattstrom L Refsum H Ueland PM Berglund L Berne C. Plasma total homocysteine and cysteine in relation to GFR in diabetes mellitus. Kidney Int. 1999 55 1028 35.
16. Henning BF Riezler R Tepel M et al. Evidence of altered homocysteine metabolism in chronic renal failure. Nephron 1999 83 314 22.
17. Jungers P Chauveau P Bandin O et al. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner. Electrolyte Metab. 1997 23 170 73.
18. Moustapha A Gupta A Robinson K et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999 55 1470 75.
19. Arnadottir M Hultberg B Nilsson Ehle P Thysell H. The effects of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand. J. Clin. Lab. Invest. 1996 56 41 6.
20. Bostom AG Shemin D Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients A prospective study. Arterioscler. Thromb. Vasc. Biol. 1997 17 2554 8.
21. Homocysteine Lowering Trialistis' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Brit. Med. J. 1998 316 894 8.
22. Rydlewicz A Simpson JA Taylor RJ Bond CM Golden MHN. The effect of folic acid supplementation on plasma homocysteine in an elderly population. Q. J. Med. 2002 95 27 35.
23. Friedman AN Bostom AG laliberty P Selhub J Shemin D. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: A randomized, controlled study. Am. J. Kidney Dis. 2003 41 442 6.
24. Trimarchi H Schiel A Freixas E Diaz M. Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients. Nephron 2002 91 58 63.
25. Massy ZA. Potential strategies to normalize the levels of homocysteine in chronic renal failure patients. Kidney Int. 2003 63 Suppl. 84 S134 S136.
26. Touam M Zingraff J Jungers P Chadefaux-Vekemans B Drueke T Massy ZA. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int. 1999 56 2292 6.
27. Slow S McGregor DO Lever M Lee MB George PM Chambers ST. Dimethylglycine supplementation does not affect plasma homocysteine concentration in pre-dialysis chronic renal failure patients. Clin. Biochem. 2004 37 974 6.
28. Beaulieu AJ Gohh RY Han H et al. Enhanced reduction of fasting homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler. Thromb. Vasc. Biol. 1999 19 2918 21.
29. Mcgregor DO Dellow WJ Robson RA Lever M George PM Chambers ST. Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. Kidney Int. 2002 61 1040 46.
30. Refsum H Ueland PM Svardal AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin. Chem. 1989 35 1921 7.
31. Sunder-Plassmann G Fodinger M. Pathophysiology and clinical importance of hyperhomocysteinemia: clinical intervention studies. Miner. Electrolyte Metab. 1999 25 286 90.
32. Zoungas S Branley P Kerr PG et al. Atherosclerosis and folic acid supplementation trial in chronic renal failure: Baseline results. Nephrology 2004 9 130 36.
33. Weiner DE Tighiouart H Stark PC et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am. J. Kidney Dis. 2004 44 198 206.
34. Weiner DE Tighiouart H Amin MG et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. 2004 15 1307 15.
35. Jungers P Massy ZA Khoa TN et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol. Dial. Tranplant. 1997 12 2597 602.
36. Mallamaci F Zoccali C Tripepi G et al., on behalf of the CREED investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002 61 609 14.
37. Campo A Goia F Cottino R Musso M Viglino G. Homocysteine, folate therapy and outcome in hemodialysis: results from a prospective study. G. Ital. Nefrol. 2003 20 484 9.
38. Hultberg B Andersson A Sternert G. Plasma homocysteine in renal failure. Clin. Nephrol. 1993 40 230 35.
39. Arnadottir M Hultber B Nilsson-Ehle P Thysell H. The effect of reduced glomerular filtration rate on plasma homocysteine concentration. Scand. J. Clin. Lab. Invest. 1996 56 41.
40. Samuelsson O Lee DM Attman PO et al. The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Nephron 1999 82 306 11.
41. Jungers P Joly D Massy Z et al. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients. Nephrol. Dial. Transplant. 1999 14 2903 6.
42. Thambyrajah J Landray MJ McGlynn FJ Jones HJ Wheeler DC Townend JN. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 2000 102 871 5.
43. Chauveau P Chadefaux B Coudé M Aupetit J Kamoun P Jungers P. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner. Electrolyte Metab. 1996 22 106 9.
44. Kang HG Lee BS Hahn H et al. Reduction of plasma homocysteine by folic acid in children with chronic renal failure. Pediatr. Nephrol. 2002 17 511 14.
45. Righetti M Ferrario G Milani S et al. Effects of folic acid on homocysteine and vascular disease in hemodialysis patients. Med. Sci. Monit. 2003 9 137 42.
46. Sunder-Plassmann G Fodinger M Buchmayer H et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients. Results of the Vienna Multicenter Study. J. Am. Soc. Nephrol. 2000 11 1106 16.
47. Dierkes J Domrose U Ambrosch A Bosselmann HP Neumann KH Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin. Nephrol. 1999 51 108 15.
48. Clarke R Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin. Thromb. Hemost. 2000 26 341 8.
49. Arnadottir M Gudnason V Hultberg B. Treatment with different doses of folic acid in haemodialysis patients: effects of folate distribution and aminothiol concentrations. Nephrol. Dial. Transplant. 2000 15 524 8.
50. Wrone EM Hornberger JM Zehnder JL McCann LM Coplon NS Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J. Am. Soc. Nephrol. 2004 15 420 26.